🔹 Revenue: $22.52B (Est. $22.46B) 🟢; UP +5.3% YoY
🔹 Adjusted EPS: $2.04 (Est. $2.02) 🟢
🔹 Net Earnings: $3.43B; DOWN -17% YoY
FY25 Guidance:
🔹 Adj Oper. EPS: $10.75-$10.95 (Est. $10.56) 🟢
🔹 Operational Sales: $90.9B-$91.7B (Est. $90.98B) 🟢
Q4 SEGMENTS:
Innovative Medicine:
🔹 Revenue: $14.33B (Est. $14.17B) 🟢; UP +4.4% YoY
🔸 Growth driven by DARZALEX ($3.08B), ERLEADA, and CARVYKTI
🔸 Offset by declines in STELARA and other neuroscience products
MedTech:
🔹 Revenue: $8.19B (Est. $8.22B) 🟡; UP +6.7% YoY
🔸 Growth supported by electrophysiology and Abiomed in cardiovascular
🔸 Wound closure products in general surgery contributed positively
Geographic Performance:
United States:
🔹 Revenue: $13.20B; UP +10.0% YoY
International:
🔹 Revenue: $9.32B; DOWN -0.7% YoY; Operational growth +2.5% YoY
Key Metrics:
🔹 Operational Sales Growth: +6.7%
🔹 Adjusted Operational Sales Growth: +5.7%
🔹 Free Cash Flow: ~$19.8B (Prev. $18.2B)
🔹 Reported EPS: $1.41; includes $(0.22) impact from acquired IPR&D charges
FY2024 Full-Year Highlights:
🔹 Revenue: $88.8B (UP +4.3% YoY); operational growth +5.9%
🔹 Adjusted EPS: $9.98 (Prev. $9.92) 🟡
🔸 Growth driven by DARZALEX, TREMFYA, and SPRAVATO
CEO Joaquin Duato's Commentary:
🔸 "2024 was transformative, marked by strong growth, pipeline acceleration, and innovations across multiple disease areas, including oncology and immunology. Johnson & Johnson remains positioned to sustain high growth and innovation."
Pipeline and Strategic Highlights:
🔸 Progress in key areas, including RYBREVANT survival data and TAR-200 submission. 🔸 Approval of investigational device exemption for the OTTAVA robotic surgery system.
